Don't Overlook Agilent (A) International Revenue Trends While Assessing the Stock

Agilent Technologies (A) reported Q1 2025 total revenue of $1.67 billion, a 6% increase, with Asia Pacific contributing $548 million (32.85% of total) and Europe $442 million (26.50%), both exceeding analyst estimates. Looking ahead, analysts project Q2 revenue at $1.66 billion, a 5.1% increase year-over-year, with Asia Pacific and Europe expected to contribute 34.6% and 25.5% respectively; full-year revenue is forecasted at $6.76 billion, up 3.8% from the previous year, highlighting the importance of monitoring international revenue trends for accurate earnings predictions amid global economic uncertainties.

Analysis

Agilent Technologies (A) demonstrated positive momentum in its international operations for the quarter ending April 2025, reporting total revenue of $1.67 billion, a 6% year-over-year increase. International segments were key contributors, with Asia Pacific revenue reaching $548 million (32.85% of total), surpassing consensus estimates by 0.65%, and Europe contributing $442 million (26.50% of total), a significant +3.77% surprise against expectations. These figures compare to Asia Pacific's $549 million (32.66%) in the prior quarter and $510 million (32.42%) in the year-ago quarter, and Europe's $463 million (27.54%) and $426 million (27.08%) respectively. Wall Street analysts project continued growth, with total revenue for the current fiscal quarter forecasted at $1.66 billion, up 5.1% year-over-year, and full-year revenue anticipated at $6.76 billion, a 3.8% improvement. International markets are expected to remain pivotal, with Asia Pacific and Europe projected to contribute 34.6% and 25.5% respectively in the current quarter, and 33.8% and 26% for the full year. While this reliance on international markets offers diversification and access to evolving economies, it also exposes Agilent to currency fluctuations and geopolitical risks. The company's stock has increased 3% over the past month, underperforming the Zacks S&P 500 composite's 6.1% rise but outperforming the Zacks Medical sector's 3.7% decrease. However, over the past three months, Agilent shares have declined 11.7%, significantly underperforming the S&P 500's 0.5% decline, though slightly better than its sector's 11.2% decrease. Agilent currently holds a Zacks Rank #3 (Hold), suggesting its performance may align with the broader market in the near term, underscoring the importance of monitoring shifts in earnings projections.

Key Decisions for Investors

• Investors should closely monitor Agilent's ability to meet its international revenue targets, particularly from Asia Pacific and Europe, as these are significant drivers of its projected 3.8% full-year revenue growth and are subject to global economic and geopolitical sensitivities.
• Given the recent positive revenue surprises from international operations but the stock's underperformance relative to the S&P 500 over the last three months (-11.7% vs -0.5%), a cautious approach is warranted, awaiting further evidence of sustained earnings momentum and market recognition.
• The Zacks Rank #3 (Hold) suggests the stock may perform in line with the market; therefore, investors might consider maintaining current positions while evaluating upcoming earnings reports and international market trends before making significant allocation changes.
• Consider the inherent risks associated with significant international revenue exposure, such as currency volatility and geopolitical instability, when assessing Agilent's long-term growth prospects and risk profile.